ERNA
Ernexa Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.36
−3.86%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
Market Cap
$7.11M
MomentumView details →
1D Return
−3.86%
YTD Return
−85.40%
RSI (14)
44.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
Market Cap
$7.11M
RSI (14)
44.9
MomentumView details →
1D Return
−3.86%
YTD Return
−85.40%
SummaryUpdated Jun 1, 2026
Eterna Therapeutics Inc. (NASDAQ:ERNA), formerly known as Brooklyn ImmunoTherapeutics, is a clinical-stage biopharmaceutical company founded in 1991 and based in Brooklyn, New York. The company focuses on developing innovative cancer treatments through immunotherapy and advanced gene-editing technologies. As a biotechnology firm in the oncology space, Eterna operates in the high-risk, high-reward pharmaceutical development sector where companies invest years and substantial capital to bring potentially life-saving treatments from laboratory research through clinical trials to market approval.
Similar companies
Latest newsMore news →
Ernexa Therapeutics appointed David Polinsky, a veteran biotech executive, to its board of directors as the company approaches the clinical stage.25d agoErnexa Therapeutics receives independent validation of its drug ERNA-101 in ovarian cancer models, showing complete tumor clearance and durable survival, ahead of planned clinical entry.51d ago